25 completed. 25 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 25 | Completed 25 |
| Phase 2 | 1 | Completed 1 |
Follow Anthrax: new trials by email Literature Review of Anthrax trials Research Report on Anthrax
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anthrax AV7909 Liquid vs Lyophilized AV7909 - Anthrax, Anthrax Immunisation | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 41 | 2022-05-25 | 2024-12-19 |
| A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants Mavacamten, Activated Charcoal with Sorbitol - Healthy Participants | Phase 1 | Completed | Bristol-Myers Squibb | 45 | 2022-04-15 | 2022-11-08 |
| Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics. Rivaroxaban, Activated charcoal - Healthy | Phase 1 | Completed | Centre Hospitalier Universitaire de Saint Etienne | 12 | 2022-01-03 | 2022-12-05 |
| NasoShield in Healthy Adults to Study Safety and Immunogenicity NasoShield, Placebo - Healthy Volunteers | Phase 1 | Completed | Altimmune, Inc. | 43 | 2020-06-15 | 2025-06-24 |
| A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults BW-1010: 50 µg - sprayer - IN, BW-1010: 50 µg - pipette - IN, BW-1010: 100 µg - sprayer - IN - Anthrax | Phase 1 | Completed | BlueWillow Biologics | 84 | 2020-01-08 | 2022-05-18 |
| NasoShield Study of Safety and Immunogenicity NasoShield, BioThrax, Placebo - Healthy Volunteers | Phase 1 | Completed | Altimmune, Inc. | 145 | 2018-01-18 | 2025-06-24 |
| A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers Symbicort pMDI with spacer device, Symbicort pMDI without spacer device - Study is Being Conducted in Healthy Volunteers | Phase 1 | Completed | AstraZeneca | 50 | 2016-11-04 | 2018-08-20 |
| Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects rivaroxaban, rivaroxaban and activated charcoal - Healthy | Phase 1 | Completed | Centre Hospitalier Universitaire de Saint Etienne | 12 | 2016-01-01 | 2016-05-25 |
| A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects Px563L, RPA563, or placebo - Anthrax | Phase 1 | Completed | Pfenex, Inc | 54 | 2015-12-01 | 2017-07-11 |
| PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine PA83-FhCMB - Anthrax | Phase 1 | Completed | Fraunhofer, Center for Molecular Biotechnology | 30 | 2014-08-01 | 2016-05-12 |
| A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines AVA, Ad4-PA-1, Ad4-PA-GPI-1 - Anthrax Infection | Phase 1 | Completed | Emergent BioSolutions | 120 | 2013-11-01 | 2024-03-18 |
| Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers ETI-204, Placebo - Inhalational Anthrax | Phase 1 | Completed | Elusys Therapeutics | 70 | 2013-07-23 | 2019-05-14 |
| Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers ETI-204, Placebo - Inhalational Anthrax | Phase 1 | Completed | Elusys Therapeutics | 280 | 2013-07-09 | 2019-04-08 |
| Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers ETI-204, "Anthim", placebo - Anthrax | Phase 1 | Completed | Elusys Therapeutics | 108 | 2011-10-01 | 2017-11-14 |
| Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects Normal Saline for Injection, MDX1303 - Anthrax | Phase 1 | Completed | PharmAthene, Inc. | 28 | 2010-12-01 | 2013-12-09 |
| Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults BioThrax, AV7909 Formulation 1, AV7909 Formulation 2 - Bacillus Anthracis (Anthrax) Infection | Phase 1 | Completed | Emergent BioSolutions | 105 | 2010-12-01 | 2024-03-18 |
| Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9) AVP-21D9, Placebo - Anthrax | Phase 1 | Completed | Emergent BioSolutions | 50 | 2010-08-01 | 2024-03-15 |
| Efficacy and Safety of Anthrax Vaccine, GC1109 Low-dose GC1109, High-dose GC1109, Low-dose Placebo - Anthrax | Phase 1 | Completed | Seoul National University Hospital | 20 | 2009-02-01 | 2013-06-05 |
| Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV) AIGIV 3.5 mg/kg, Gamunex 90 mg/kg, AIGIV 7.0 mg/kg - Anthrax | Phase 1 / Phase 2 | Completed | Emergent BioSolutions | 129 | 2009-02-01 | 2024-03-18 |
| Foster With or Without Charcoal Block or Aerochamber Plus charcoal block, Aerochamber Plus spacer, pMDI standard actuator - Healthy Volunteers | Phase 1 | Completed | Chiesi Farmaceutici S.p.A. | 13 | 2006-12-01 | 2020-08-03 |
Showing 20 of 25. Sign in to see all of them.
Inhalation anthrax (2) · Poisoning (2) · Asthma (1) · HIV Infections (1) · Infections (1) · Pulmonary Disease, Chronic Obstructive (1)
Bacillaceae Infections (25) · Bacterial Infections (25) · Bacterial Infections and Mycoses (25) · Gram-Positive Bacterial Infections (25) · Infections (24) · Chemically-Induced Disorders (2) · Immune System Diseases (2) · Blood-Borne Infections (1) · Bronchial Diseases (1) · Chronic Disease (1) · Communicable Diseases (1) · Disease Attributes (1) · Genital Diseases (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1)
Anthrax Vaccines (4) · Biothrax (4) · Charcoal (4) · obiltoxaximab (4) · Metered Dose Inhalers (2) · Rivaroxaban (2) · Sodium Chloride (2) · AVP-21D9 (1) · Blood Chemical Analysis (1) · Ciprofloxacin (1) · Hematologic Tests (1) · Immunoglobulins, Intravenous (1) · Injections (1) · MYK-461 (1) · Saline Solution (1)
Emergent BioSolutions (4) · Elusys Therapeutics (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Altimmune, Inc. (2) · Centre Hospitalier Universitaire de Saint Etienne (2) · AstraZeneca (1) · BlueWillow Biologics (1) · Bristol-Myers Squibb (1) · Chiesi Farmaceutici S.p.A. (1) · DynPort Vaccine Company LLC, A GDIT Company (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Fraunhofer, Center for Molecular Biotechnology (1) · Pfenex, Inc (1) · PharmAthene, Inc. (1) · Seoul National University Hospital (1)
United States (20) · France (2) · South Korea (1) · Switzerland (1) · United Kingdom (1)
Alex King, MD (1) · Antonio Rusca, MD, FMH (1) · Barbara K Lomeli, M.D. (1) · Clay W. Mash, Ph.D. (1) · David Mathews, MD (1) · Debra Mandarino, MD (1) · Dr Rainard Fuhr, Dr. med (1) · Edward Bernton, MD (1) · Eleanor A Lisbon, M.D., M.P.H (1) · Emanuel DeNoia, MD (1) · H. Frank Farmer, PhD, MD (1) · Hubert C Chen, M.D. (1)
PMID 27568215, PMID 21079762, PMID 21615456, PMID 23701746, PMID 23979731, PMID 24733473, PMID 27910037, PMID 34544599, PMID 35153091, PMID 38926266
2015 (1), 2016 (1), 2019 (1)